Correction to: APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy (Hepatology International, (2021), 15, 5, (1031-1048), 10.1007/s12072-021-10239-x)
Issued Date
2022-04-01
Resource Type
ISSN
19360533
eISSN
19360541
Scopus ID
2-s2.0-85123506604
Pubmed ID
35076895
Journal Title
Hepatology International
Volume
16
Issue
2
Start Page
486
End Page
487
Rights Holder(s)
SCOPUS
Bibliographic Citation
Hepatology International Vol.16 No.2 (2022) , 486-487
Suggested Citation
Lau G. Correction to: APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy (Hepatology International, (2021), 15, 5, (1031-1048), 10.1007/s12072-021-10239-x). Hepatology International Vol.16 No.2 (2022) , 486-487. 487. doi:10.1007/s12072-022-10301-2 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/87345
Title
Correction to: APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy (Hepatology International, (2021), 15, 5, (1031-1048), 10.1007/s12072-021-10239-x)
Author(s)
Author's Affiliation
Yamanashi Prefectural Central Hospital
Siriraj Hospital
Institute of Liver and Biliary Sciences
Beijing Friendship Hospital, Capital Medical University
Kaohsiung Medical University Chung-Ho Memorial Hospital
National Taiwan University Hospital
Mongolian National University of Medical Sciences
General Hospital of People's Liberation Army
Universitas Indonesia, RSUPN Dr. Cipto Mangunkusumo
National Cancer Center, Gyeonggi
The Aga Khan University Hospital
The University of Tokyo
National Center for Global Health and Medicine
University of Macau
Royal Prince Alfred Hospital
Singapore General Hospital
University of Malaya Medical Centre
Ankara Üniversitesi
Prince of Songkla University
Chinese University of Hong Kong
Southern Medical University
United Christian Hospital Hong Kong
St. Vincent's Hospital Melbourne
Cardinal Santos Medical Center
Nork Clinical Hospital of Infectious Diseases
Yangon GI and Liver Centre
Humanity and Health Clinical Trial Center
Siriraj Hospital
Institute of Liver and Biliary Sciences
Beijing Friendship Hospital, Capital Medical University
Kaohsiung Medical University Chung-Ho Memorial Hospital
National Taiwan University Hospital
Mongolian National University of Medical Sciences
General Hospital of People's Liberation Army
Universitas Indonesia, RSUPN Dr. Cipto Mangunkusumo
National Cancer Center, Gyeonggi
The Aga Khan University Hospital
The University of Tokyo
National Center for Global Health and Medicine
University of Macau
Royal Prince Alfred Hospital
Singapore General Hospital
University of Malaya Medical Centre
Ankara Üniversitesi
Prince of Songkla University
Chinese University of Hong Kong
Southern Medical University
United Christian Hospital Hong Kong
St. Vincent's Hospital Melbourne
Cardinal Santos Medical Center
Nork Clinical Hospital of Infectious Diseases
Yangon GI and Liver Centre
Humanity and Health Clinical Trial Center
Other Contributor(s)
Abstract
Unfortunately, the first and last name of the Co-author, Tawesak Tanwandee has been interchanged in the original publication of the article. The correct first name should read as “Tawesak” and the last name should read as “Tanwandee” respectively.